Here is an oldie but a goodie...of course these were either outright lies to defraud investors or he is the absolute worst person to ever head a company ...the jackoff is a total failure when it comes to creating products and revenue for shareholders...he has twin California addresses..one is only a high profile street name with no access to building...lmao....the newest is a two day per month rental that is used by traveling salesmen...go figure ..anyway here are some more Dabney lies..
You will have to carefully read his back to back inhaler press releases to understand that he had to back up and say we are begining protocols the day after he announced that the product was to be on the shelves of Cali clinics within days...
Anyway here are dabneys words..lmao he choke on them..jackoff loser
May 25, 2012
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science, Inc. (CBIS.OB), a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide insight on the upcoming release of its’ new over-the-counter skin and nutraceutical product line to be branded “Phytiva” through its newest venture Phytiva Pharmaceuticals Inc. The Company is working as fast as it can to make its cannabis-based formulations that target critical ailments more widely available through multiple regulatory body guidelines. This approach will allow the Company to release its formulations to multiple markets reaching the maximum amount of people in the shortest time frame across the nation and internationally. To support this cause Cannabis Science has been working with numerous patients who have been documenting their self-medicating treatment process using the cannabis-extracts.
The Company continues to receive a large number of inquiries about current and new product releases and operational updates on its projects in the works. The Company is in the process of updating its website to provide up-to-date timeline information on its projects, product lines, events, conferences and other important corporate and operational information for the public as released for the public.
FDA Initiatives
Cannabis Science is working very close with its previously announced FDA clinical trials consultants to guide the Company through the formal FDA new product release regulatory guidelines. The main steps required to be completed are as follows:
1. Pre-IND meeting with the FDA
*** The Company is currently in this stage and is working close with its’ FDA advisory group towards requesting a pre-IND meeting date. The Company has identified its initial target indication as skin cancer and will present this case to the FDA at the pre-IND meeting.
2. Application filing for IND – Number
Once the Company has presented its case at the pre IND meeting with the FDA and makes any recommended adjustments to its case study, it will then submit its formal application to the FDA for the IND number application.
3. IND – Number assignment
FDA will assign an IND number for the case study once the Company has completed a successful application process. The IND number assignment will give the Company the green light to begin its clinical trials.
4. Begin clinical trials
Once the Company has successfully completed the application process and receives its IND number from the FDA it can then begin formal clinical trials to prove the product viable for general market consumption or use.
5. Successful IND product release
Working within the FDA regulatory procedures is paramount for Cannabis Science. Once it receives full approvals from the FDA on each of its target indications, it will then release its products for patients in need of the treatments for their critical ailments nationwide.
Over-the-counter Nutraceutical Product Lines
This market opportunity for the Company and the people who are looking for Cannabis Science formulations is very large and spans the nation and beyond. The Company has identified several target products to release and is finalizing a few for immediate OTC market release. Our supporters recognize that these products will help finance the company as we move forward with the FDA process.
Cannabis Science is rapidly moving to commercialize Phytiva, our new over-the-counter skin and nutraceutical product line to be available through its newest venture Phytiva Pharmaceuticals Inc. Cannabis Science formulations for these new products are finalized and we are making decisions for mass manufacturing and nationwide distribution. With several products on the roster for the Phytiva product line, the Company has made public a few: a lip balm to improve the dryness of lips and promote healing, a sunscreen with dual purposes to block the sun, promote sunburn healing and relief, and a dry skin lotion that enhance skin care for those suffering with Eczema and Psoriasis, a fourth product is a facial and body moisturizer that contains compounds with anti-aging properties that promote healthy skin and appearance.
As we develop the initial products for the Phytiva Product line, Cannabis Science is working on laterally expansion as we negotiate to acquire new and effective products and treatment processes.
State Regulated Medical Cannabis Dispensaries
The Company target initiatives in states that have approved medical marijuana programs is based on the successful results being reported by patients self-medicating using Cannabis Science approved formulations through state licensed manufacturers and distributors. The Company is working to expand availability of our formulations across the nation on a state-by-state basis as states continue to approve medical cannabis treatments.
Currently, Cannabis Science has its cannabis-based high quality extract formulations available in Pueblo and Denver Colorado through licensing agreements. As well, The Company has signed a licensing deal with Apothecary Genetics in California to provide the same full circle operations required under State regulated medical cannabis laws to provide California State licensed medical cannabis patients its formulations.
The Company has been receiving outstanding feed back from the current patients using its formulations for Skin Cancer as documented on the www.cannabisscience.com website
AI
Market Data 
Markets 
